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ABSTRACT
Objectives: The presence of thyroglobulin (Tg) in needle washouts of fine needle aspiration biopsy 
(Tg-FNAB) in neck lymph nodes (LNs) suspected of metastasis has become a cornerstone in the follow-
up of patients with papillary thyroid carcinoma (PTC). However, there are limited data regarding the 
measurement of anti-Tg antibodies in these washouts (TgAb-FNAB), and it is not clear whether these 
antibodies interfere with the assessment of Tg-FNAB or whether there are other factors that would 
more consistently justify the finding of low Tg-FNAB in metastatic LNs. Materials and methods: 
We investigated 232 FNAB samples obtained from suspicious neck LNs of 144 PTC patients. These 
samples were divided according to the patient’s serum TgAb status: sTgAb- (n = 203 samples) and 
sTgAb+ (n = 29). The TgAb-FNAB levels were measured using two different assays. Tg-FNAB was 
also measured using two assays when low levels (< 10 ng/mL) were identified in the first assay 
of the metastatic LNs from the sTgAb+ samples. Results: The TgAb-FNAB results were negative in 
both assays in all samples. Low levels of Tg-FNAB were identified in 11/16 of the metastatic LNs of 
the sTgAb+ patients and 16/63 of the sTgAb- patients (p < 0.05) using assay 1. The measurement of 
the Tg-FNAB levels using assay 2 indicated additional metastases in 5 LNs of the sTgAb+ patients. 
Conclusions: Factors other than the presence of TgAb-FNAB may contribute to the higher number 
of metastatic LNs with undetectable Tg-FNAB in the sTgAb+ group. In addition, the measurement of 
Tg-FNAB using different assays was useful to enhance the diagnosis of metastatic LNs, particularly 
when cytological and Tg-FNAB results are discordant. Arch Endocrinol Metab. 2017;61(2):108-14
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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, with a propensity for cervical 
lymphatic spread, which occurs in 20% to 50% of patients 
based on reports of surgical pathological specimens using 
standard methods of description; however, the prevalence 
may reach 90% of patients when the surgical sample is 
scrutinized in detail for micrometastases (1,2).
The confirmation of malignancy in lymph nodes (LNs) 
with a suspicious ultrasonographic (US) appearance is 
achieved by US-guided fine needle aspiration biopsy 
(FNAB) for cytological study (cyto-FNAB) and the 
measurement of thyroglobulin levels (Tg) in needle 
washouts (Tg-FNAB) (3-8).
Considering only the data from cyto-FNAB, 
approximately 6% to 8% of metastases are misdiagnosed 
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as a result of false-negative results (9,10). These results 
may occur in cases of small or cystic LN metastases, 
which reflect a lack of tumor cells detected during the 
FNAB procedure (11). Nevertheless, the use of Tg-
FNAB alone has several limitations, and despite being 
well established as an important tool in the investigation 
of suspicious LN metastases, Tg-FNAB presents 
variable results between metastatic and non-metastatic 
LNs (3,4,11-23). This subject has been the topic of 
recent reviews and meta-analysis studies (12,13). 
Another aspect for consideration during the follow-
up of patients with PTC is the interpretation of serum 
Tg (sTg) values in the presence of serum anti-Tg 
antibodies (sTgAb), which occurs in approximately 25% 
of patients with PTC; these antibodies may interfere 
with the measurement of sTg, which compromises the 
use of this tumor marker in the follow-up of patients 
with PTC (24). It remains controversial whether these 
antibodies also interfere with the assessment of TgAb-
FNAB. Previous studies on this topic have included a 
limited number of patients with positive serum anti-
Tg antibodies (sTgAb+) (25-27) and limited direct 
measurements of TgAb-FNAB (16,18,20,25,26). 
Therefore, the objectives of the present study were 
to: 1) assess the presence of TgAb in a substantial 
amount of washout fluid samples (TgAb-FNAB) of 
cervical LNs suspicious for PTC metastases; 2) analyze 
whether the presence of serum sTgAb+ interfered with 
the assessment of Tg-FNAB for the management of neck 
lymphadenopathy in PTC patients; and 3) compare the 
TgAb values of the serum and FNAB washout. 
MATERIALS AND METHODS
Patients
We assessed 144 patients who presented suspicious LNs 
via US assessment during follow-up for PTC. These 
patients were followed by a single team of physicians at 
associated Thyroid Disease Centers at the Division of 
Endocrinology, Department of Medicine, Escola Paulista 
de Medicina, Universidade Federal de Sao Paulo and the 
Instituto Israelita de Ensino e Pesquisa Albert Einstein, 
both in Sao Paulo, Brazil.
Suspicious LNs were submitted to FNAB guided by 
neck US assessment. The minimum follow-up period 
was 4 years after the last FNAB. Some patients had more 
than one FNAB performed when multiple suspicious 
LNs appeared during the follow-up or the FNAB had 
to be repeated because of inadequate or non-diagnostic 
cyto-FNAB results with undetectable Tg-FNAB values. 
Two hundred eighty-six FNABs were performed, 
and 232 FNAB samples were analyzed. Fifty-four 
FNAB samples were excluded because the patients 
were lost during follow-up (n = 32) or the diagnosis 
of lymphadenopathy could not be confirmed (n = 22), 
as cytopathology indicated that these samples were 
obtained from other cervical lesions rather than LNs. 
The confirmation of LN metastases was obtained via 
histopathological examination after surgery or the 131I 
uptake after radioiodine treatment. In two particular 
situations, LNs that initially fulfilled suspicious criteria 
via US assessment were considered reactive over 
time: 1) LNs that spontaneously disappeared at the 
subsequent US assessment performed during follow-
up; and 2) LNs that initially had inadequate or non-
diagnostic cytology results on the first FNAB attempt 
and presented a reactive cytology with Tg-FNAB 
< 10 ng/mL after a second FNAB.
All diagnostic procedures were performed in 
accordance with the regulations of the local ethics 
committee. Written informed consent was obtained 
from each patient.
Assays
Tg-FNAB was measured with a commercial 
immunofluorometric assay using monoclonal 
antibodies (DELFIA®, PerkinElmer, Turku, Finland), 
with a functional sensitivity of 1.0 ng/mL (assay 1). A 
second immunofluorometric Tg assay (assay 2), using 
mono and polyclonal antibodies, was performed on the 
washout fluids of sTgAb+ patients with a Tg-FNAB 
value < 10 ng/mL in assay 1 to determine whether 
low Tg-FNAB persisted using a different method. 
Assay 2 has a functional sensitivity of 0.3 ng/mL (28). 
The Tg assay 2 was assessed only in this specific group 
of patients for whom the TgAb-FNAB results, in the 
case of positivity by contamination with sTgAb, could 
interfere with the Tg-FNAB levels. We verified whether 
these lower Tg-FNAB levels would be maintained 
when examined using another assay. 
The Tg-FNAB cutoff point for the diagnosis of 
malignancy has not been unanimously established in 
the literature (12,13). We used the value of 10 ng/mL, 
which is consistent with the majority of published 
reports (11,14,20-22).
TgAb was measured using an in house 
immunofluorometric assay in both serum and FNAB 
washout samples, and negative values for TgAb were 
considered < 40 IU/mL (29). In addition, we also 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
110
Thyroglobulin and anti-thyroglobulin antibodies in needle washouts
Arch Endocrinol Metab. 2017;61/2
measured TgAb in FNAB washout samples using a 
chemiluminescence immunoassay (ECLIA Roche, 
Mannheim, Germany). The cutoff value for positive 
TgAb was 115 IU/mL.
Ultrasonography
A cervical US assessment was performed using a linear, 
multi-frequency, 7.5-10-MHz transducer and integrated 
using color-Doppler examination by the same radiologist. 
The images were obtained in transversal and longitudinal 
planes by scanning the hyperextended neck, which 
enabled the visualization of the central compartment. All 
cervical LNs were identified, localized, and measured. 
LNs with 1 or more suspicious features indicative of PTC 
neck metastasis, i.e., round shape, hypoechogenic aspect, 
absence of hilum, non-homogeneous pattern, including 
fluid areas, and intralesional punctate calcifications, were 
submitted to FNAB.
Cyto-FNAB and Tg-FNAB
US-guided FNAB was performed using a 22-25-gauge 
needle attached to a 10-mL syringe inserted into 
the LN under US visual control. The needle was 
repeatedly moved inside each LN until the needle hub 
was filled with material. The smears (4-8 per LN) were 
immediately fixed and stained with panoptic dye. All 
cytological examinations were performed by the same 
cytopathologist.
The cyto-FNAB results were classified into 3 
distinct diagnostic categories: 1) reactive: presence 
of lymphocytes and occasional plasma cells without 
malignant epithelial cells; 2) inadequate or non-
diagnostic: presence of blood cells and absence of 
inflammatory and epithelial cells; and 3) positive for PTC 
metastases: presence of epithelial cells with malignant 
cytological characteristics (e.g., abnormal nuclear shape, 
nuclear enlargement and nuclear polymorphisms, 
presence of papillae, and/or characteristic nuclear 
changes, such as grooves and pseudo-inclusions).
Following the smear preparation, the needle 
was washed with 1 mL of saline, and the solution 
was processed for Tg-FNAB measurement and 
subsequently stored at -20°C. The same samples were 
used to measure the TgAb-FNAB levels.
Statistical analysis
The number of metastatic LNs in Group 1 (sTgAb-) and 
Group 2 (sTgAb+), as well as their Tg-FNAB levels (assay 
1) and cyto-FNAB results were compared using Fisher’s 
Exact Tests and χ2 tests as appropriate, with a two-tailed 
p < 0.05 considered statistically significant. The sensitivity, 
specificity, positive predictive value and negative predictive 
value of a positive Tg-FNAB were calculated using assay 
1 (Tg-FNAB ≥ 10 ng/mL). All analyses were performed 
using the Statistical Package for Social Science professional 
software version 15.0 (SPSS, Chicago, IL, USA). 
RESULTS 
A general overview of the present study that indicates 
the results of 232 FNABs in 144 patients is presented 
in Figure 1. The patients were divided into 2 groups: 
Group 1, which included patients who presented 
negative sTgAb values (sTgAb-) (203 FNABs), and 
Group 2, which included patients who presented 
positive sTgAb values (sTgAb+) (29 FNABs). These 
groups were subsequently subdivided according to 
the Tg-FNAB levels (Tg-FNAB ≥ 10 ng/mL and 
Tg-FNAB < 10 ng/mL) and the cyto-FNAB results 
(reactive, inadequate/non-diagnostic or positive for 
PTC metastasis) (Figure 1).
We identified metastases in 63 (31%) LNs in Group 
1 (sTgAb-) and 16 (55%) LNs in Group 2 (sTgAb+). 
This difference was statistically significant (p < 0.05, 
Fisher’s Exact test) (Table 1). All metastatic LNs 
presented classical and follicular PTC histological 
variants. 
 Sixteen of the 63 metastatic LNs in Group 1 and 
11 of the 16 metastatic LNs in Group 2 had Tg-FNAB 
levels < 10 ng/dL. Therefore, Group 2 (sTgAb+) had a 
higher number of metastatic LNs with Tg-FNAB values 
< 10 ng/dL than Group 1 (68.8% in Group 2 vs. 25.4% 
in Group 1; p < 0.05, χ2 test) (Table 1). Consistent 
with the serum results, this finding suggests that the 
presence of sTgAb may underestimate the measurement 
of Tg-FNAB. 
The cutoff of Tg-FNAB of 10 ng/mL (assay 1) 
for the diagnosis of metastatic PTC in cervical LNs 
in Group 1 (sTgAb-) exhibited a sensitivity of 74.6%, 
with a specificity of 100%, a positive predictive value of 
100% and a negative predictive value of 89.7%; Group 
2 (sTgAb+) exhibited a sensitivity of 31.2%, with a 
specificity of 100%, a positive predictive value of 100% 
and a negative predictive value of 54.2%. Notably, it 
was not possible to perform the same analysis for Tg-
FNAB using assay 2 because it was only tested in the 
washout fluids of the sTgAb+ patients with Tg-FNAB 
levels < 10 ng/mL in assay 1.
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Table 1. Comparison of Tg-FNAB levels (assay 1) and cyto-FNAB results of metastatic lymph nodes from Group 1 (sTgAb-) and Group 2 (sTgAb+)
GROUP 1 sTgAb-Metastatic/TOTAL (%) 63 / 203 (31%)a GROUP 2 sTgAb+Metastatic/TOTAL (%) 16 / 29 (55%)a
Tg-FNAB < 10 ng/mL Tg-FNAB ≥ 10 ng/mL Tg-FNAB < 10 ng/mL Tg-FNAB ≥ 10 ng/mL
n n n n
Inadequate/not diagnostic 
cyto-FNAB
13 20 5 0
Positive for metastasis 
cyto-FNAB
3 27 6 5
TOTAL 16 (25.4%)b 47 (74.6%)c 11 (68.8%)b 5 (31.3%)c
a Statistical difference between groups (p < 0.05) using Fisher’s Exact Test 2 test.      
b,c Statistical difference between groups (p < 0.05) using  χ2 test.      
Total of FNAB excluded: 54
– 32 patients did not completed the determined follow-up
– In 22 FNABs the diagnosis of lymphadenopathy could 
 not be conrmed
144 patients
286 FNABs
Group 1: Serum TgAb –
203 FNABs
Positive cyto-FNAB 
for PTC
metastasis 
n = 27
Positive cyto-FNAB for
PTC metastasis 
n = 6
Inadequate/Not
diagnostic 
cyto-FNAB
n = 20
Inadequate/Non
diagnostic cyto-FNAB
n = 5
Inadequate/Not
diagnostic 
cyto-FNAB
n = 13
Positive cyto-FNAB
for PTC 
metastasis
n = 3
Positive cyto-FNAB
for PTC metastasis
n = 5 (all)
47/47 metastatic 
LNs conrmed by
histopathology 
or 131I uptake
16/156 metastatic 
LNs conrmed by
histopathology 
or 131I uptake
5/5 metastatic LNs 
conrmed by
histopathology 
or 131I uptake
11/24 metastatic LNs 
conrmed by
histopathology 
or 131I uptake
Tg-FNAB < 10 ng/mL
n = 156
Tg-FNAB ≥ 10 ng/mL
n = 5
Tg-FNAB ≥ 10 ng/mL
n = 47
Group 2: Serum TgAb +
29 FNABs
232 FNABs
Tg-FNAB < 10 ng/mL
n = 24
Figure 1. General overview of the study with detailing of Tg-FNAB (by assay 1-(immunofluorometric, with monoclonal antibodies) and cyto-FNAB results 
of Group 1 (sTgAb–) and Group 2 (sTgAb+).
To evaluate the potential differences in the 
performance of Tg assay 1 in the sTgAb+ patients 
(Group 2), we performed a different Tg-FNAB assay 
(using mono and polyclonal antibodies, Tg assay 2) in all 
washout fluid samples of metastatic LNs with Tg-FNAB 
levels < 10 ng/mL using assay 1 (using monoclonal 
antibodies). We obtained different results between 
both assays in 4 patients whose cyto-FNABs were 
positive for PTC metastases and the levels of Tg-FNAB 
were low (< 10 ng/mL) according to assay 1 and high 
(≥ 10 ng/mL) according to assay 2 (Table 2). In these 
patients, the measurements of Tg-FNAB using assay 2 
were consistent with the cyto-FNAB measurements. 
These findings also indicated that the presence of 
sTgAb could interfere with the interpretation of Tg-
FNAB measurements. Furthermore, these findings 
suggest methods that employ polyclonal antibodies, 
such as radioimmunoassays and assay 2, appeared more 
resistant to TgAb interference (24). Moreover, in 
one patient, a suspicious LN based on US assessment 
presented inadequate/non-diagnostic cyto-FNAB, 
and the level of Tg-FNAB was 8.7 ng/mL according 
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to assay 1 and 142 ng/mL according to assay 2. This 
patient underwent 131I treatment, and the subsequent 
scintigraphy indicated substantial 131I uptake in the 
area of the corresponding LN. Consequently, in this 
patient, the measurement of Tg-FNAB using assay 2 
was important for the diagnosis of metastasis.
However, the direct measurement of TgAb-FNAB 
based on immunofluorometric assays was negative in 
all 232 samples of both groups, including the FNAB 
washouts of the sTgAb+ patients. Using a second assay 
(electrochemiluminescence assay, ECLIA, Roche), we 
identified 7 samples with positive TgAb-FNAB values, 
all of which were obtained from Group 1 (sTgAb-) 
patients, with high levels of Tg-FNAB, which likely 
lead to false elevations of TgAb-FNAB. Moreover, this 
artifact represents an established competitive effect that 
occurs when the Tg levels are > 2000 ng/mL, and 
these values must be considered false-positive results, 
as described by the manufacturer. 
The presence of TgAb in FNAB washout fluids 
may reflect the active LN synthesis of TgAb (30) or 
the contamination of the washout fluids with blood; 
thus, we measured the TgAb-FNAB levels in both 
positive and negative sTgAb patients (n = 232). The 
results indicated that all washout fluid samples obtained 
from the patients in both groups were negative for 
TgAb-FNAB based on immunofluorometric assays. 
Notably, when we retested the TgAb-FNAB levels 
using a chemiluminescence immunoassay, we identified 
7 samples in Group 1 (sTgAb-) patients with positive 
TgAb-FNAB values. However, as previously described, 
these patients had extremely high levels of Tg-FNAB, 
and according to the manufacturer’s description, these 
results must be interpreted as false-positive because 
of the high titers of Tg-FNAB. We thus considered 
that all washout fluid samples of Groups 1 and 2 were 
negative for TgAb-FNAB in both assays performed. 
However, we raised several speculations to justify the 
negative results of TgAb-FNAB in all samples in the 
present study, including the samples obtained from 
sTgAb+ patients: 1) active LN synthesis of TgAb, 
which may eventually occur, was scarce in the samples, 
and consequently, there was no detection of TgAb in 
the washouts; 2) there was no contamination of the 
washout fluid with blood during the FNAB procedure 
in the sTgAb+ patients; and 3) the washouts of LNs 
perfused with blood that contain TgAb may have a 
low concentration of these antibodies; however, it is 
insufficient to measure. 
Other studies have presented similar results. 
Following the inclusion of a limited number of TgAb-
FNAB measurements of LN washout in sTgAb+ 
patients, the authors did not detect TgAb via direct 
measurement in the washout fluids of LNs, which 
suggests that sTgAb do not interfere with the detection 
of Tg-FNAB levels (16,18,20,26). 
Boi and cols. evaluated washout fluid samples from 
8 sTgAb+ patients and suggested that the presence of 
TgAb-FNAB may interfere with the interpretation of 
Tg-FNAB results because lower levels of Tg-FNAB 
were detected in 2 metastatic LNs with positive 
TgAb-FNAB levels compared with metastatic LNs 
with negative TgAb-FNAB levels (25). These authors 
proposed that this interference is minimized by the 
high Tg concentrations in the FNAB washouts of 
metastatic LNs, which saturate TgAb binding sites and 
therefore do not compromise the value of Tg-FNAB in 
the diagnosis of metastases. The results of the present 
Table 2. Comparison of Tg-FNAB by assay 1 (immunofluorometric, with 
monoclonal antibodies) and assay 2 (immunofluorometric with mono and 
polyclonal antibodies) and cytological results of metastatic lymph nodes 
(LNs) of Group 1 (sTgAb-) and Group 2 (sTgAb+) with Tg-FNAB levels < 
10 ng/mL by assay 1
Tg-FNAB 
Assay 1
Tg-FNAB 
Assay 2
Reactive cyto-FNAB – –
Inadequate/not diagnostic cyto-FNAB 8.7 142
< 1.0 1.6
< 1.0 0.5
< 1.0 0.9
< 1.0 0.6
Positive for metastasis cyto-FNAB < 1.0 28.6
5.9 42.7
< 1.0 142
< 1.0 1.4
2.1 101
< 1.0 1.1
DISCUSSION 
The evaluation of cervical LNs is difficult during the 
follow-up of PTC patients because inflammatory LNs 
are frequently present. The use of Tg-FNAB is well 
recognized as a valuable instrument in the examination 
of suspicious LN metastases (3,4,11-23). However, 
there are limited data regarding factors that may interfere 
with the diagnostic sensitivity of Tg-FNAB, such as the 
presence of TgAb in washout fluid samples.
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study, which included a larger number of patients 
(11/24 patients sTgAb+ and Tg-FNAB < 10 ng/mL, 
Group 2, Figure 1), confirm this finding. 
TgAb-FNAB was negative in all samples examined 
in the present study; thus, further comparisons between 
the TgAb values in the serum and FNAB washout 
would not be plausible. Instead, we considered other 
potential reasons why low levels of Tg-FNAB were 
present in the metastatic LNs of patients with PTC, 
including difficulties in sampling a representative area 
of neoplasia during the FNAB procedure, heterogenic 
Tg production by metastatic cells and differences in Tg 
assay performance.
Regarding the difficulties in sampling a representative 
area of neoplasia during FNAB, we identified metastatic 
LNs with Tg-FNAB < 10 ng/mL in both Group 1 (n 
= 16) and Group 2 (n = 11). We proposed that this 
Tg-FNAB value represented a true negative result in 
most cases based on the finding that the majority of 
these LNs also exhibited inadequate/non-diagnostic 
cyto-FNAB results (Group 1: n = 13/16 and Group 
2: n = 5/11) (Table 1). However, this result may also 
reflect the non-homogeneous patterns and fluid areas 
that occur in some metastatic LNs. 
In the present study, we did not identify 
undifferentiated variants of PTC carcinoma in 
metastatic LNs with low Tg-FNAB levels (< 10 ng/mL). 
In both Groups 1 and 2, all metastatic LNs with low 
Tg-FNAB values presented classical and follicular PTC 
histological variants. However, variable levels of Tg-
FNAB have been described, even in samples with the 
same variant, which reflects heterogenic Tg production 
by differentiated metastatic cells (24). 
Differences in Tg assays were also identified in the 
present study. The finding of negative TgAb-FNAB in 
all samples and a higher percentage of metastatic LNs 
with Tg-FNAB < 10 ng/dL in the sTgAb+ patients than 
the sTgAb- patients (68.75% vs. 25.4%, respectively, 
p < 0.05) prompted us to perform a second Tg assay in 
the washout fluids of all proven metastatic LNs of the 
sTgAb+ patients with Tg-FNAB < 10 ng/dL (Table 2). 
In some patients, we obtained different results between 
both assays. The Tg-FNAB levels according to assay 2 
were consistent with the cytological results in 4 LNs 
with positive cyto-FNAB for PTC metastasis with 
undetectable Tg-FNAB based on assay 1, and these 
LNs were metastatic. The Tg-FNAB level of 142 ng/mL 
detected using assay 2 also clarified the diagnosis of a 
metastatic LN with inadequate/non-diagnostic cyto-
FNAB and a Tg-FNAB level of 8.7 ng/mL according 
to assay 1 (Table 2).
Similar to the results obtained in the present 
study, Jeon and cols. (27) and Jo and cols. (31) also 
identified a higher percentage of LNs with low levels 
of Tg-FNAB in sTgAb+ patients than sTgAb- patients. 
These authors concluded that the presence of sTgAb 
interfered with the Tg-FNAB levels; however, these 
researchers did not measure TgAb in FNAB washout 
fluid samples (27,31). 
In conclusion, we propose that other factors, rather 
than the presence of TgAb, may contribute to the 
higher number of metastatic LNs with undetectable 
Tg-FNAB identified in the sTgAb+ group because 
TgAb-FNAB was negative in all samples according 
to 2 different assays. Furthermore, for the analysis of 
Tg-FNAB in the sTgAb+ patients, assay 2 (mono/
polyclonal) had a better performance in the detection 
of metastatic LNs than the monoclonal assay; however, 
it exhibited limitations in the identification of some 
LN metastases. Nevertheless, this analysis was useful 
in some cases in which there was no concordance 
between the cyto-FNAB and Tg-FNAB results or 
when the cyto-FNAB was inadequate/non-diagnostic 
and the Tg-FNAB levels were low based on the 
monoclonal assay. Therefore, we proposed that the 
measurement of Tg using another assay would be 
helpful in LNs with a positive cytology for PTC and 
low levels of Tg-FNAB using the first assay and in 
cases of inadequate/non-diagnostic cytology and low 
Tg-FNAB levels. However, in this latter situation, 
we emphasize that the low value of Tg-FNAB may 
persist in every additional assay assessed, as a matter 
of material scarcity. When employed alone, cyto-FNAB 
or Tg-FNAB (independent of the tested assay) did not 
provide a guarantee of establishing the diagnosis of 
cervical lymphadenopathy in patients. 
In addition, false-positive and false-negative results 
may occur, which reinforce the recommendations that 
these LNs require monitoring and physicians must 
interpret clinical, laboratory, cytology, and ultrasound 
data together to achieve successful management in the 
follow-up of patients with PTC. 
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